Floatz logo

Arsenic Trioxide

Myeloid Malignancy

Ruijin HospitalSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

30 Active assets in the Myeloid Malignancy cohort.

Asset / SponsorPhaseRating
Mitoxantrone
First Affiliated Hospital of Zhejiang University
Phase 3BBB
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 3BBB
Cladribine
University of Washington
Phase 2BBB
Cyclophosphamide
Prelude Therapeutics
Phase 3BB
Idarubicine
Northwestern University
Phase 3BB

View all 49 →

Same molecule, other indications

Arsenic Trioxide is also rated in:

acute promyelocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
71 / 100
View asset →
central nervous system neoplasmDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →